{"title":"Erythropoietin: Functions and Therapeutic Potential","authors":"A. P. Lykov","doi":"10.1134/s1990519x2401005x","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Abstract</h3><p>Erythropoietin (EPO) exerts its effect on erythroid cells through interaction with the EPO receptor (EPOR), the so-called “canonical pathway,” and through a complex consisting of EPOR and the common cytokine receptor β subunit (CD131)—a noncanonical pathway for non-hematopoietic cells of the bodies of human beings and animals. The effect of EPO is realized through the initiation of a signaling cascade, which begins with phosphorylation of Janus kinase 2 (JAK2) and extends with the involvement of phosphatidylinositol 3 kinase B (PI3K), Ras-mitogen-activated protein kinase (MAPK), or signal transducers and activators of transcription (STAT). EPO exerts a direct cytoprotective effect through increased expression of CD131 with subsequent antiapoptotic and anti-inflammatory effects in target cells. In addition to its use in the treatment of anemia, EPO is increasingly used in the correction of inflammatory and degenerative processes in both experimental and clinical cell-mediated studies. EPO promotes the engraftment of stem cells and differentiation of mesenchymal stem cells in the connective tissue direction, suppressing the inflammatory response and apoptosis of cells in the lesion. The article includes literature data regarding EPO and its clinical use in inflammatory–degenerative processes based on eLibrary and National Center for Biotechnology Information data from 1998 to 2022.</p>","PeriodicalId":9705,"journal":{"name":"Cell and Tissue Biology","volume":"49 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell and Tissue Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1134/s1990519x2401005x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0
Abstract
Erythropoietin (EPO) exerts its effect on erythroid cells through interaction with the EPO receptor (EPOR), the so-called “canonical pathway,” and through a complex consisting of EPOR and the common cytokine receptor β subunit (CD131)—a noncanonical pathway for non-hematopoietic cells of the bodies of human beings and animals. The effect of EPO is realized through the initiation of a signaling cascade, which begins with phosphorylation of Janus kinase 2 (JAK2) and extends with the involvement of phosphatidylinositol 3 kinase B (PI3K), Ras-mitogen-activated protein kinase (MAPK), or signal transducers and activators of transcription (STAT). EPO exerts a direct cytoprotective effect through increased expression of CD131 with subsequent antiapoptotic and anti-inflammatory effects in target cells. In addition to its use in the treatment of anemia, EPO is increasingly used in the correction of inflammatory and degenerative processes in both experimental and clinical cell-mediated studies. EPO promotes the engraftment of stem cells and differentiation of mesenchymal stem cells in the connective tissue direction, suppressing the inflammatory response and apoptosis of cells in the lesion. The article includes literature data regarding EPO and its clinical use in inflammatory–degenerative processes based on eLibrary and National Center for Biotechnology Information data from 1998 to 2022.
期刊介绍：
The journal publishes papers on vast aspects of cell research, including morphology, biochemistry, biophysics, genetics, molecular biology, immunology. The journal accepts original experimental studies, theoretical articles suggesting novel principles and approaches, presentations of new hypotheses, reviews highlighting major developments in cell biology, discussions. The main objective of the journal is to provide a competent representation and integration of research made on cells (animal and plant cells, both in vivo and in cell culture) offering insight into the structure and functions of live cells as a whole. Characteristically, the journal publishes articles on biology of free-living and parasitic protists, which, unlike Metazoa, are eukaryotic organisms at the cellular level of organization.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
